Identification

Name
Fluticasone furoate
Accession Number
DB08906
Type
Small Molecule
Groups
Approved
Description

Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. Despite the similarity in the names, fluticasone furoate and fluticasone propionate are different drugs with different properties. It is marketed under the brand name, Veramyst in the US by GlaxoSmithKline for the management of chronic obstructive pulmonary disease (COPD). FDA approved on April 27, 2007.

Fluticasone furoate is available as a combination product with vilanterol, a long-acting beta-2 agonist, under the tradename Breo Ellipta. Approved by the FDA in 2013, its use is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease.

Structure
Thumb
Synonyms
  • Fluticasone furoate
  • Fluticasonum furoas
  • Furoate de fluticasone
  • Furoato de fluticasona
External IDs
GSK 685698 / GW-685698X / GW685698X
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arnuity ElliptaPowder100 mcgOral; Respiratory (inhalation)Glaxosmithkline Inc2016-01-26Not applicableCanada
Arnuity ElliptaPowder100 ug/1Respiratory (inhalation)Glaxosmithkline Inc2014-08-20Not applicableUs
Arnuity ElliptaPowder50 ug/1Respiratory (inhalation)Glaxosmithkline Inc2018-05-17Not applicableUs
Arnuity ElliptaPowder200 mcgOral; Respiratory (inhalation)Glaxosmithkline Inc2015-12-14Not applicableCanada
Arnuity ElliptaPowder200 ug/1Respiratory (inhalation)Glaxosmithkline Inc2014-08-20Not applicableUs
AvamysSpray, metered27.5 mcgNasalGlaxosmithkline Inc2007-10-22Not applicableCanada
AvamysSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-01-11Not applicableEu
AvamysSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-01-11Not applicableEu
AvamysSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-01-11Not applicableEu
VeramystSpray, metered27.5 ug/1NasalPhysicians Total Care, Inc.2010-09-07Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Flonase Sensimist Allergy ReliefSpray, metered27.5 ug/1NasalGlaxoSmithKline Consumer Healthcare Holdings (US) LLC2017-07-01Not applicableUs
Flonase Sensimist Allergy ReliefSpray, metered27.5 ug/1NasalGlaxoSmithKline Consumer Healthcare Holdings (US) LLC2017-02-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Breo ElliptaFluticasone furoate (200 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)Glaxo Operations UK Ltd2015-04-302018-01-08Us
Breo ElliptaFluticasone furoate (100 mcg) + Vilanterol (25 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc2013-11-29Not applicableCanada
Breo ElliptaFluticasone furoate (200 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)Glaxosmithkline Inc2015-04-30Not applicableUs
Breo ElliptaFluticasone furoate (100 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)Remedy Repack2016-04-042016-04-05Us
Breo ElliptaFluticasone furoate (200 mcg) + Vilanterol (25 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc2015-10-02Not applicableCanada
Breo ElliptaFluticasone furoate (100 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)Glaxosmithkline Inc2013-08-26Not applicableUs
Breo ElliptaFluticasone furoate (200 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)A-S Medication Solutions2015-04-30Not applicableUs
Breo ElliptaFluticasone furoate (100 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)Glaxo Operations UK Ltd2013-08-262018-01-08Us
Trelegy ElliptaFluticasone furoate (100 mcg) + Umeclidinium (62.5 mcg) + Vilanterol (25 mcg)PowderRespiratory (inhalation)Glaxosmithkline IncNot applicableNot applicableCanada
Trelegy ElliptaFluticasone furoate (100 ug/1) + Umeclidinium bromide (62.5 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)GlaxoSmithKline LLC2017-09-18Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AlisadeFluticasone furoate (27.5 micrograms/spray)Spray, suspensionIntrasinalGlaxo Group Limited2008-10-062011-10-18Eu
AlisadeFluticasone furoate (27.5 micrograms/spray)Spray, suspensionIntrasinalGlaxo Group Limited2008-10-062011-10-18Eu
AlisadeFluticasone furoate (27.5 micrograms/spray)Spray, suspensionIntrasinalGlaxo Group Limited2008-10-062011-10-18Eu
Categories
UNII
JS86977WNV
CAS number
397864-44-7
Weight
Average: 538.576
Monoisotopic: 538.163693965
Chemical Formula
C27H29F3O6S
InChI Key
XTULMSXFIHGYFS-VLSRWLAYSA-N
InChI
InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl furan-2-carboxylate
SMILES
[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C

Pharmacology

Indication

Fluticasone furoate nasal spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older.

Breo Ellipta, a mixture of fluticasone furoate and vilanterol is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease. Breo Ellipta should not be used for the relief of acute symptoms of asthma or COPD.

Associated Conditions
Pharmacodynamics

Fluticasone furoate binds to human glucocorticoid receptor more potently than dexamethasone (29.9-times) and fluticasone propionate (1.7-times). It also is highly retained in respiratory tissue. The significance of this finding is that fluticasone furoate may have a more pronounced and prolonged anti-inflammatory effect, which allows for once-daily dosing. It does not have any effect on the QTc interval. Furthermore, fluticasone furoate was not found to affect the hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma.

Mechanism of action

Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. The precise mechanism through which fluticasone furoate affects rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Specific effects of fluticasone furoate demonstrated in in vitro and in vivo models included activation of the glucocorticoid response element, inhibition of pro-inflammatory transcription factors such as NFkB, and inhibition of antigen-induced lung eosinophilia in sensitized rats. Fluticasone is also found to increase airway retention of long-acting beta adrenergic agonist, thus potentiating its beneficial effects for the treatment of asthma.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Following intranasal administration of fluticasone furoate, most of the dose is eventually swallowed and undergoes incomplete absorption and extensive first-pass metabolism in the liver and gut, resulting in negligible systemic exposure. Even at the highest recommended intranasal dose of 110 mcg once daily, plasma concentrations were not quantifiable. This is an especially useful feature as it lowers the incidence of adverse events associated with corticosteroid use. If administered using oral solution and intravenous dosing, 30% of the drug is absorbed and rapidly cleared from the plasma. Absolute bioavailability, intranasal route = 0.5%; Absolute bioavailability, oral route = 1.26%; Mean lung absorption time = 7 hours (regardless of formulation);

Volume of distribution

Steady state, IV administration = 608 L

Protein binding

>99% protein bound.

Metabolism

Fluticasone furoate does not undergo cleavage into its two separate components, fluticasone and the furoate moiety. It undergoes extensive hepatic metabolism via CYP3A4. The principal route of metabolism is hydrolysis of the S-fluoromethyl carbothioate function to form the inactive 17β-carboxylic acid metabolite. Studies suggest that enterocytes may be involved in the metabolism of unabsorbed drug.

Route of elimination

Fluticasone furoate and its metabolites are eliminated primarily in the feces, accounting for approximately 101% and 90% of the orally and intravenously administered dose, respectively. Urinary excretion accounted for approximately 1% and 2% of the orally and intravenously administered dose, respectively. Fluticasone furoate is extensively metabolized so very little is excreted unchanged.

Half life

Elimination phase half-life, IV dose = 15.1 hours; Elimination phase half-life, inhaled = 17 - 24 hours;

Clearance

Total plasma clearance = 58.7 L/h

Toxicity

The most common adverse reactions (>1% incidence) included headache, epistaxis, pharyngolaryngeal pain, nasal ulceration, back pain, pyrexia, and cough.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Fluticasone furoate.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Fluticasone furoate.
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Fluticasone furoate.
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Fluticasone furoate.
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Fluticasone furoate.
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluticasone furoate.
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Fluticasone furoate.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Fluticasone furoate.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Fluticasone furoate.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Fluticasone furoate.
Food Interactions
Not Available

References

Synthesis Reference

Adrienne KOVACSNE-MEZEI, Roman Gabriel, Alexandr Jegorov, "POLYMORPHS OF FLUTICASONE FUROATE AND PROCESSES FOR PREPARATION THEREOF." U.S. Patent US20100240629, issued September 23, 2010.

US20100240629
General References
  1. Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L: Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013 Oct;7(4):397-406. doi: 10.1111/crj.12026. Epub 2013 Jun 5. [PubMed:23578031]
  2. Tamm M, Richards DH, Beghe B, Fabbri L: Inhaled corticosteroid and long-acting beta2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med. 2012 Dec;106 Suppl 1:S9-19. doi: 10.1016/S0954-6111(12)70005-7. [PubMed:23273165]
  3. Allen A, Bareille PJ, Rousell VM: Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013 Jan;52(1):37-42. doi: 10.1007/s40262-012-0021-x. [PubMed:23184737]
External Links
KEGG Drug
D06315
PubChem Compound
9854489
PubChem Substance
175427145
ChemSpider
8030195
BindingDB
50354851
ChEBI
74899
ChEMBL
CHEMBL1676
HET
GW6
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fluticasone_furoate
ATC Codes
R03AK10 — Vilanterol and fluticasone furoateR01AD12 — Fluticasone furoateR03BA09 — Fluticasone furoate
AHFS Codes
  • 52:08.08 — Corticosteroids
PDB Entries
3cld
FDA label
Download (469 KB)
MSDS
Download (70.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAsthma Bronchial2
1CompletedBasic ScienceAsthma Bronchial1
1CompletedOtherAsthma Bronchial1
1CompletedPreventionAsthma Bronchial / Healthy Volunteers1
1CompletedTreatmentAsthma Bronchial1
1CompletedTreatmentAsthma Bronchial / Healthy Volunteers1
1CompletedTreatmentAsthma Bronchial / Hepatic Impairment1
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
2CompletedTreatmentAsthma Bronchial12
2CompletedTreatmentOesophagitis, Eosinophilic1
2Not Yet RecruitingTreatmentAsthma Bronchial1
2RecruitingDiagnosticChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Perennial1
3CompletedTreatmentAsthma Bronchial11
3CompletedTreatmentHayfever Allergic Rhinitis Seasonal Rhinitis / Rhinitis, Allergic, Seasonal1
3CompletedTreatmentHayfever / Rhinitis, Allergic, Seasonal / Seasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR) / Rhinitis, Allergic, Perennial2
3CompletedTreatmentPerennial Allergic Rhinitis (PAR) / Rhinitis, Allergic, Perennial and Seasonal / Seasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentPulmonary Disease, Chronic Obstructive3
3CompletedTreatmentRhinitis1
3CompletedTreatmentRhinitis, Allergic, Perennial2
3CompletedTreatmentRhinitis, Allergic, Perennial / Seasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentRhinitis / Rhinitis, Allergic, Perennial1
3CompletedTreatmentVasomotor Rhinitis2
4CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)1
4CompletedBasic ScienceChildhood Obstructive Sleep Apnea Syndrome (OSAS)1
4CompletedOtherRhinitis, Allergic, Perennial and Seasonal1
4CompletedOtherSeasonal Allergic Rhinitis (SAR)1
4CompletedTreatmentAllergic Conjunctivitis to Tree Pollen or Grass Pollen1
4CompletedTreatmentAllergic Rhinitis (AR)2
4CompletedTreatmentAsthma Bronchial1
4CompletedTreatmentRhinitis, Allergic, Perennial / Seasonal Allergic Rhinitis (SAR)2
4CompletedTreatmentRhinitis, Allergic, Seasonal2
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
4RecruitingTreatmentAsthma Bronchial1
4Unknown StatusTreatmentPatients With Nasal Polyps1
4WithdrawnTreatmentAllergic Rhinitis (AR)1
4WithdrawnTreatmentAsthma Bronchial1
Not AvailableCompletedNot AvailableCognition / Driving Ability / Seasonal Allergic Rhinitis (SAR)1
Not AvailableCompletedNot AvailableRhinitis, Allergic, Perennial / Rhinitis, Allergic, Seasonal1
Not AvailableCompletedTreatmentAllergic Rhinitis (AR)1
Not AvailableRecruitingNot AvailableAsthma Bronchial1
Not AvailableTerminatedTreatmentAsthma Bronchial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Spray, suspensionIntrasinal27.5 micrograms/spray
PowderOral; Respiratory (inhalation)100 mcg
PowderOral; Respiratory (inhalation)200 mcg
PowderRespiratory (inhalation)100 ug/1
PowderRespiratory (inhalation)200 ug/1
PowderRespiratory (inhalation)50 ug/1
Spray, meteredNasal27.5 mcg
PowderRespiratory (inhalation)
Spray, meteredNasal27.5 ug/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5873360Yes1999-02-232016-08-23Us
US6858596No2005-02-222021-08-03Us
US7101866No2006-09-052021-08-03Us
US7541350No2009-06-022021-08-03Us
US8347879No2013-01-082028-07-15Us
US8752543No2014-06-172026-04-05Us
US8062264No2011-11-222026-04-05Us
US8147461No2012-04-032028-10-15Us
US7439393No2008-10-212022-09-11Us
US6759398No2004-07-062021-08-03Us
USRE44874No2014-04-292023-03-23Us
US6537983No2003-03-252021-08-03Us
US8511304No2013-08-202027-06-14Us
US7629335No2009-12-082021-08-03Us
US8161968No2012-04-242028-02-05Us
US8746242No2014-06-102030-10-11Us
US8113199No2012-02-142027-10-23Us
US7776895No2010-08-172022-09-11Us
US8534281No2013-09-172029-08-10Us
US6878698No2005-04-122021-08-03Us
US8309572No2012-11-132025-04-27Us
US8183257No2012-05-222025-07-27Us
US7488827No2009-02-102025-04-27Us
US7498440No2009-03-032025-04-27Us
US8201556No2012-06-192029-02-05Us
US9320862No2016-04-262024-11-06Us
US9333310No2016-05-102027-10-02Us
US9750726No2017-09-052030-11-29Us
US9750762No2017-09-052030-11-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
pKa6 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0434 mg/mLALOGPS
logP3.73ALOGPS
logP4.13ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area93.81 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity130.08 m3·mol-1ChemAxon
Polarizability51.55 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9917
Blood Brain Barrier+0.9666
Caco-2 permeable-0.5222
P-glycoprotein substrateSubstrate0.7675
P-glycoprotein inhibitor IInhibitor0.784
P-glycoprotein inhibitor IIInhibitor0.604
Renal organic cation transporterNon-inhibitor0.8329
CYP450 2C9 substrateNon-substrate0.8023
CYP450 2D6 substrateNon-substrate0.8893
CYP450 3A4 substrateSubstrate0.7205
CYP450 1A2 substrateNon-inhibitor0.6493
CYP450 2C9 inhibitorNon-inhibitor0.7288
CYP450 2D6 inhibitorNon-inhibitor0.8305
CYP450 2C19 inhibitorNon-inhibitor0.6388
CYP450 3A4 inhibitorInhibitor0.9211
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.69
Ames testNon AMES toxic0.747
CarcinogenicityNon-carcinogens0.9079
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6232 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9787
hERG inhibition (predictor II)Non-inhibitor0.566
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Androgens and derivatives / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Furoic acid esters / Heteroaromatic compounds / Thioesters / Secondary alcohols / Carbothioic S-esters
show 11 more
Substituents
Steroid ester / Androgen-skeleton / Androstane-skeleton / Hydroxysteroid / Halo-steroid / 6-halo-steroid / 9-halo-steroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid
show 34 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
thioester, 11beta-hydroxy steroid, steroid ester, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, corticosteroid, 2-furoate ester (CHEBI:74899)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. FDA reports [Link]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. [PubMed:26721703]
  2. FDA reports [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Hughes SC, Shardlow PC, Hollis FJ, Scott RJ, Motivaras DS, Allen A, Rousell VM: Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab Dispos. 2008 Nov;36(11):2337-44. doi: 10.1124/dmd.108.022137. Epub 2008 Aug 11. [PubMed:18694910]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. FDA reports [Link]

Drug created on June 16, 2013 17:03 / Updated on December 18, 2018 05:46